Serum and whole blood microRNA (miRNA) fingerprints have been proposed as a new class of non-invasive human cancer biomarkers. In this study, we compared equine sarcoid (ES) diseasespecific serum and whole blood miRNA fingerprints and correlated them to miRNA expression in sarcoid tissue. After high throughput sequencing, miRNA differential expression analysis between six ES-affected and five control horses was carried out in serum and whole blood using a DESeq algorithm, accounting for the influence of hemolysis and the white blood cell count.
| INTRODUCTION
Sarcoids are benign, but locally invasive fibroblastic tumours and represent the most common equine skin neoplasm worldwide. 1 Equine sarcoid (ES) disease is a multifactorial condition with bovine papilloma viruses (BPV) 1, 2 and 13 [2] [3] [4] [5] and trauma 6 besides host genetic susceptibility 7, 8 playing major roles in its etiopathogenesis. In general, clinical diagnosis of ES disease has a good reliability. However, for unclear or atypical cases, there is a need for reliable, non-invasive biomarkers.
Definite diagnostic confirmation requires histopathological examination of a biopsy specimen, but taking a biopsy carries itself the risk of disease aggravation. 6 Detection of BPV-DNA from swabs or scrapings collected from the tumour surface has been proposed as a less invasive, easy, fast and cheap diagnostic method for most sarcoid cases, but may lack sensitivity if minimal epidermal changes are present. 9, 10 MicroRNAs (miRNAs) are small non-coding RNAs (typically [19] [20] [21] [22] [23] nucleotides), that target and silence complementary mRNAs. 11 Aberrant miRNA expression is associated with numerous diseases in mammalian species 12, 13 including different types of cancer, where miRNAs can either exert oncogenic or tumour-suppressor functions. 14 Recently, dysregulation of miRNA expression in BPV-1 transformed equine fibroblasts 15 and in equine sarcoid tissue has been reported. 16 Circulating, cell-free miRNAs have been proposed as a new promising class of cancer biomarkers due to their high stability in plasma and serum 17, 18 which is guaranteed by either association with proteins of the Argonaute (AGO) family or transport in RNase resistant microvesicles like exosomes. 19 Hemolysis caused by sample preparation can influence miRNA contents in serum and plasma due to red blood cell contamination and thus warrants particular attention in biomarker studies. 20, 21 Whole blood as a source for miRNA biomarker discovery has lately been proposed. [22] [23] [24] It contains more RNA than serum or plasma, enabling precise miRNA expression measurements with small sample volumes. 22 Furthermore, pre-analytical errors related to handling of serum or plasma can be avoided. Finally, whole blood miRNA profiling allows to not only measure tumour secreted miRNAs but also to evaluate changes in miRNA fingerprints related to the body's systemic response to cancer, possibly also in the early course of the disease. 23, 24 However, it is recommended to evaluate miRNA expression levels always in light of blood cell counts, since they can change miRNA levels by up to 50-fold. 25 The goal of this study was to compare ES disease-specific miRNA profiles in serum and whole blood by taking into account preanalytical variables such as hemolysis and white blood cell counts, to correlate them to highly expressed miRNAs in ES tissue and to interpret the biological implications of the computational output with regard to the etiopathogenesis of ES disease.
| MATERIALS AND METHODS

| Study cohort
A case-control study was conducted to identify differences in miRNA expression profiles between sarcoid affected horses and control horses. All animal experiments were performed according to the local regulations and with the consent of the horse owners. This study was approved by the Animal Experimentation Committee of the Canton of Bern, Switzerland (BE110/15). Horses allocated to the category "sarcoid-affected" had to fulfil the following inclusion criteria: referred to the ISME equine clinic for surgical excision of sarcoid lesions, histo- 4, 26 The control group consisted of long-term well monitored clinic-owned horses that were historically free of sarcoid lesions and also free of any signs of systemic disease at the time of examination. As ES is reported to be a disease of young horses, 27 only middle-aged and old horses (≥12 years) were included in the control group in order to lower the risk that they might still develop ES disease.
| Sample collection, RNA extraction, evaluation of preanalytical variables and high throughput sequencing
Whole blood of sarcoid-affected and control horses were collected from the jugular vein into serum and EDTA tubes. For serum separation, blood was allowed to clot in serum tubes at room temperature for 30 minutes and then centrifuged at 1400g for 10 minutes. Serum was transferred to cryotubes (Sarstedt, Nümbrecht, Germany) and stored at −80 C until further use. Whole blood was directly transferred from EDTA tubes to cryotubes and as well stored at −80 C.
RNA extraction from serum and whole blood using miRNeasy serum/ Any miRNA candidate with a predicted miRDeep2 score of 0 was considered as a potential miRNA. To filter for predicted potential novel horse-specific miRNAs with high confidence, a miRDeep2 score cut-off of 2 was used. With a score cut-off of 2 we did not have any known miRNA overlapping novel miRNAs. Any two overlapping novel miRNAs (by at most 1 nucleotide) were merged with BEDTools. 37 The high quality novel and known miRNAs were then quantified using quantifier.pl module. The CSV files produced by quantifier.pl containing the read count for all known and novel miRNAs were used for further statistical analysis. The predicted miRNAs were also filtered for those showing a BLAST match to a tRNA or rRNA.
| Differential expression analysis in serum and whole blood
The raw counts of the high quality novel and known miRNAs were used for differential expression analysis with DESeq2 (v. 1.14.1). 38 We removed lowly expressed miRNAs (showing zero counts in more than 10% of samples). The "DESeq" function estimates size factors and dispersions and fits a model in order to perform differential expression tests using negative binomial generalized linear models.
Since the P-value distribution of DESeq2 was skewed with a hill shape, the fdrtool was used to re-estimate the P-values 39 after estimating the null variance which was less than one. The BenjaminiHochberg method was used for adjusting the P-values. For corrected P-values, significance was set at P < 0.05. The expression profile variation between and within the sarcoid-affected and control group was determined by principal component analysis (PCA). The complete pipeline for analysis of next generation sequencing (NGS) output data is summarized in Figure 1 .
| Tissue ranking
The expression values for miRNA expressed in the five tissue samples were estimated using the miRDeep2 package as explained above. The expression values were then ranked in each of the samples and a rank product was calculated via the geometric mean. 40 The miRNA genes with the lowest rank were considered to be highly expressed in all sample replicates.
| Target gene prediction, enrichment and pathway analysis
Enrichment analysis with GeneCodis 41-43 was performed using target genes of differentially expressed miRNAs in serum and whole blood of ES-affected vs control horses determined by TarBase v7.0 (Diana Tools), 44 which catalogues only published experimentally validated miRNA: gene interactions. Pathway prediction was performed using mirPath v.3 (Diana Tools). 45 3 | RESULTS
| Study cohort and RNA quality and quantity
Six ES-affected horses and five control horses met the inclusion criteria. Breed, sex and age of all horses as well as type, localization and number of sarcoids in the sarcoid-affected group are reported in (Table 2 ). In comparison to humans, horses have physiologically higher bilirubin concentrations. 46, 47 Thus, absorbance of bilirubin, which peaks between 400 and 540 nm, 48 will overlap with absorbance of oxyhemoglobin, when measured at 414 nm. Consequently, we chose to repeat assessment of the level of hemolysis using the Cobas 6000 analyser that first, measures haemoglobin absorbance at higher wavelengths (600/570 nm), that do not interfere with bilirubin absorbance, and second, corrects the values for absorption related to lipemia, generating a so-called hemolysis index. 30 The hemolysis index correlated perfectly with the results of visual inspection of the serum samples:
| Evaluation of pre-analytical variables
it was >15 in only those four samples that also grossly appeared 
| Sequence data analysis
High-throughput sequencing data was analysed according to the pipeline presented in Figure 1 . A total of 3 098 847 AE 536 560 reads from the serum libraries and 8 622 638 AE 1 022 672 from the whole 
and known miRNA. The core algorithm of miRDeep2, reported a total of 1044 putative novel miRNAs with a miRDeep2 score between 0 and 10. A total of 567 miRNAs remained after filtering for known tRNA, rRNA match, a miRDeep score of 2 and those that showed a non-significant randfold P-value suggesting the secondary structure was unlikely to match the one of a miRNA precursor. This resulting set of high confidence novel miRNAs is listed in Supporting Information Table S1 .
3.5 | miRNA differential expression in serum Figure S1 ).
| Target gene prediction, enrichment and pathway analysis for miRNAs differentially expressed in serum
The single novel miRNA20_16168 without a known human homologue was excluded from the analysis. Using TarBase v7.0 (Diana Tools), 195 target genes with a prediction score of ≥0.9 (suggested threshold for stringent analysis) were predicted for eight differentially expressed miRNAs in the sarcoid vs control groups (Table S3) . Singular enrichment analysis of KEGG pathways by GeneCodis showed enrichment for "pathways in cancer" (26.9%) and "cell cycle" (19.2%) (Table S4 ). The mirPath v.3 (Diana Tools) predicted 46 pathways for the differentially expressed miRNAs in the sarcoid vs control group (Pvalue <0.05) with 9 of the top 10 pathways being cancer-associated pathways, (Table S5 ).
| miRNA differential expression in whole blood
A total of 19 differentially expressed miRNAs were identified in whole blood of ES-affected vs control horses with an adjusted P-value <0.05 and a fold change of ≥2 and ≤ 6 in either direction (Table 4) . Nine miRNAs (47.4%) were upregulated and 10 miRNAs (52.6%) were downregulated in the whole blood of ES-horses. The principal component analysis (PCA) is depicted in Figure S1 . None of the miRNAs differentially expressed in whole blood were differentially expressed in serum after exclusion of hemolyzed samples. When hemolyzed samples were included, a total of 10 out of 19 miRNAs (52%) dysregulated in whole blood were also differentially expressed in serum and this overlap was likely because of red blood cell contamination of serum. Abbreviations: ES, equine sarcoid; cx, control; WB, warmblood; FM, Franches-Montagnes; f, mare; m, stallion; mc, gelding; fb, fibroblastic; mfb, mixed fibroblastic; DSS, disease severity score; WBC, white blood cell count; RIN, RNA integrity nu.
| Target gene prediction, enrichment and pathway analysis for miRNAs differentially expressed in whole blood
Seven novel miRNAs without known human homologues were excluded from the analysis. Using TarBase v7.0 (Diana Tools), 957 target genes with a prediction score of ≥0.9 were predicted for 12 differentially expressed miRNAs in the sarcoid vs control groups (Table S6 ).
Singular enrichment analysis of KEGG pathways by GeneCodis revealed the "MAPK signaling pathway" among the top enriched pathways, which is involved cell proliferation and migration 49 (Table S7) .
GeneTerm Linker Analysis provided a set of five functional metagroups, of which three showed enrichment for cancer associated pathways (Table S8) (Table S9 ).
| miRNA gene expression ranking in ES tumour tissue
Because we did not have any control tissue to check for differential expression of miRNA compared to tumour tissue, we used rank product 40 to check for high to low expression of miRNA genes in tumour tissue (Table S10 ). Out of the top 100 highly expressed miRNAs in sarcoid tissue 2 (both downregulated) out of 9 (22.2%) miRNAs were also differentially expressed in serum and seven (6 downregulated, 1 upregulated) out of 19 (36.8%) in whole blood (Table 5) .
Pathway prediction for the target genes of the 2 downregulated miRNAs in serum, that were highly expressed in tissue, predicted 6 pathways, that are all potentially associated with cancer (Table 5 ).
There was enrichment for metabolic pathways involved in lipogenesis 
| DISCUSSION
After accounting for pre-analytical variables, serum and whole blood miRNA profiles allowed non-invasive diagnosis of fibroblastic and mixed-fibroblastic sarcoid lesions in horses without a biopsy. However, miRNA expression in serum was substantially influenced by the level of hemolysis, which complicates differential expression analysis and favours the use of whole blood for further biomarker studies.
Pathways associated with miRNA differential expression in serum and whole blood of horses with ES disease showed obvious enrichment for cancer-associated pathways-irrespective of the software tool used. Pathway prediction relies, however, mainly on results from human cancer tissue studies and it is unknown how well results can be extrapolated to circulating miRNAs. 19 Thus, further pathway analysis was focused on miRNAs simultaneously dysregulated in blood and at tissue level. 
50-52
Shedding of miRNAs from tumour cells can render the tumour environment more permissive to growth and invasion 53 and decrease anti-tumorigenic effects to maintain oncogenesis. 54 In this study, only two differentially expressed miRNAs in serum (eca-miR-486-5p and eca-miR-100) were among the top 100 highly expressed miRNAs in sarcoid tissue. Eca-miR-100 upregulation has already been described in sarcoid tissue. 16 In human medicine depending on tumour type, eca-miR-486 and eca-miR-100 have been described to possess both tumoursuppressive [55] [56] [57] [58] [59] and oncogenic functions, [60] [61] [62] and are downregulated in serum and plasma. 63, 64 The excretion of eca-miR-486-5p and eca-miR-100 from sarcoid tissue, where they are highly expressed and may exert oncogenic effects, into the bloodstream seems to be limited and results in low expression in the serum of sarcoidaffected horses. This is particularly interesting for eca-miR-486, which under physiological conditions is a highly abundant miRNA in equine plasma. 65 Seven miRNAs that were dysregulated in whole blood of horses with ES diseases were highly expressed in sarcoid tissue in this study, among them eca-let-7 g and eca-miR-125b-5p. Members of the let-7-family (eca-let-7a, eca-let-7e and eca-let-7f ) and eca-miR-125b-5p, have been found to be upregulated in sarcoid tissue in a previous study. 16 Furthermore, eca-miR-199a-5p, eca-miR-199b-5p, eca-miR20a, eca-miR-let-7 g and eca-miR-181a, all of them found highly expressed in sarcoid tissue in our study, were upregulated in BPV-1-transformed equine fibroblasts. 15 MiR-199b-5p and miR-20a seem to possess oncogenic functions in human HPV-associated cervical cancer by enhancing cell proliferation and migration. 66, 67 Interestingly, circulating let-7 g was significantly downregulated in whole blood of dogs with skin cancer, 68 as observed in this study in horses with equine sarcoids.
miRNA differential expression for ES-affected vs control horses did not show common dysregulated miRNAs in both serum and whole blood. This is in accordance with previous human and animal studies that showed that miRNAs are not only specific for different tissues, but also for different components of blood. 69, 70 In whole blood, white blood cells are the richest source of RNA and thus contribute substantially to miRNA expression patterns. 71 White blood cell counts were normal in all whole blood samples and did not have to be taken into account for miRNA differential expression analysis. Besides this, the use of whole blood as input material for this miRNA study revealed a further advantage: The mean RNA concentration in whole blood was more than four times higher compared to serum, which decreases the risk to miss low expressed miRNAs. Lastly, the retrieved quality of RNA from whole blood samples was adequate even if samples were stored initially without addition of RNA-stabilizing agents, which confirmed the result of a previous study. 28 Extracellular miRNAs in serum are most likely to originate from non-blood cells, 72 but can be contaminated by miRNAs from hemolyzed erythrocytes, which might bias serum miRNA expression profiles. 25 In order to account for hemolysis in serum samples in this study, we could not rely on measuring absorbance at 414 nm, as is routinely performed in other mammalian species, due to mild physiological hyperbilirunbinemia in horses and overlap of absorbance spectra of haemoglobin and bilirubin at this wavelength. Other studies on equine serum miRNA expression also found unexpectedly high absorbance at 414 nm, which would have classified 58%-100% of serum samples as hemolyzed using the standard cut-off of 0.3.
73-75
The use of the hemolysis index generated by the Cobas 6000 analyser overcame the problem of bilirubin interference. Even if visual inspection correlated perfectly with the hemolysis index in this study, it is in general not a reliable method for detection of hemolysis. 76 All samples with a hemolysis index >15 were excluded from miRNA differential expression analysis as recommended in the Standard Operating Procedure (SOP) for collection of serum released by the National Cancer Institute (U.S. National Institutes for Health). 77 After exclusion of hemolyzed samples the number of differentially expressed miRNAs in serum of ES-affected vs control horses was greatly diminished, which confirms the substantial influence of hemolysis on miRNA expression.
One of the potential limitations of this study is the significant difference in mean age of ES-affected and control horses. Agerelated alterations in miRNA profiles have been described in humans. 78, 79 We were, however, specifically searching for control horses older than 12 years without previous history of ES-disease in order to minimize the risk that they may still develop ES disease. Little is known about breed related differences in serum miRNA profiles. So far only differences in serum miRNA profiles between Warmblood horses and ponies have been detected. 75 ES-affected and controlhorses included in our study comprised three different, but genetically Lysine degradation 9.87E-07 23 6 Abbreviations: down, downregulated; up, upregulated; high, highly expressed.
In this study, serum and whole blood miRNA fingerprints allowed classification of horses as sarcoid-affected or control horses and partly correlated with tissue miRNA profiles. Owing to the small sample size included, these experiments must be considered as a pilot study.
Thus, the suitability of the differentially expressed miRNAs as potential diagnostic biomarkers warrants further validation in a larger study cohort comprised of horses of various breeds and ages and suffering from different clinical types of equine sarcoids. Furthermore, qRT-PCR may replace next generation sequencing to assess miRNA expression levels in the future, which would render the whole procedure less cost-and time-consuming. Lastly, there are risks of pre-analytical errors, particularly from hemolysis, when analysing serum for miRNA fingerprints. Since white blood cell counts are usually within normal limits in ES-affected horses and are thus less likely to falsify miRNA differential expression, whole blood may be considered as a valuable alternative input material for future miRNA studies.
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